AMBER: Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Sponsor

Celgene Corporation (Industry)

Overall Status

Terminated

CT.gov ID

NCT02655159

Collaborator

(none)

Enrollment

Locations

Duration (Months)

2.4

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. The study will be conducted by reviewing the medical records of patients up to the start of the study. In each case, only data from before the start of the study will be obtained in order to ensure they are retrospective in nature, thus reflecting the regular use of nab-paclitaxel in clinical practice and avoiding interference with the physician's clinical practice.

To ensure the observational nature of this study, these data will be collected whenever they are available in the patient's medical record, and so no diagnostic or therapeutic intervention outside regular clinical practice will be used.

Condition or Disease	Intervention/Treatment	Phase
Breast Neoplasms

Detailed Description

This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. Investigators will include all consecutive adult patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014). These patients must meet all the inclusion criteria and none of the exclusion criteria established in this protocol.

The primary objective is to describe the effectiveness of nab-paclitaxel in terms of response in early lines of chemotherapy for metastatic breast cancer in routine clinical practice.

This study plans to collect data retrospectively, provided they are available in the patient's medical record and according to routine clinical practice.

Study Design

Study Type:

Observational

Actual Enrollment :

46 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

Study Start Date :

Jan 1, 2016

Actual Primary Completion Date :

Aug 1, 2016

Actual Study Completion Date :

Aug 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Abraxane® treatment in patients with metastatic breast cancer Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.

Outcome Measures

Primary Outcome Measures

Overall response rate (ORR) [Up to approximately 8 months]
The number of patients who achieve a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria during treatment with nab-paclitaxel until disease progression, the end of treatment or the start of the study, whichever comes first.

Secondary Outcome Measures

Overall Response Rate (ORR) [Up to approximately 8 months]
The number of patients who achieve a complete response (CR) or partial response (PR) during the first 3 treatment cycles with nab-paclitaxel and the corresponding 95% CI will be calculated.
Disease control rate (DCR) [Up to approximately 8 months]
The percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) for at least 16 weeks, and the corresponding 95% confidence intervals (CI) will be calculated.
Time to disease progression (TTP) [Up to approximately 8 months]
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death due to progression. TTP will be estimated by using the Kaplan-Meier method. The median and confidence interval for the median at 95% reliability (95% CI) will be calculated. In patients who show no disease progression or who have not died, the date of censoring may be the day on which the patient's death is documented, the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Progression-free survival (PFS) [Up to approximately 8 months]
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death from any cause. PFS will be estimated by using the Kaplan-Meier method. Patients who have shown no disease progression or who have not died at the time of data collection will be censored on the date on which it was last known that no disease progression occurred. The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Overall survival (OS) [Up to approximately 8 months]
Is defined as the time from the start of treatment with nab-paclitaxel to death from any cause. OS will be estimated by using the Kaplan-Meier method. Patients who have not died at the time of data collection will be censored on the date on which they are last known to be alive. The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Adverse Events (AEs) [Up to approximately 8 months]
Number of participants with adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Women ≥18 years of age.
Confirmed diagnosis of MBC (stage IV).
Breast adenocarcinoma confirmed histologically.
HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.
Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.
Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).

Exclusion Criteria:

Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.
Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.
Patients who have taken part in any clinical trial (interventional) during the study period.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Complejo Hospitalario Jaén	Jaén	Andalucía	Spain	23007
2	Hospital Clínico Lozano Blesa	Zaragoza	Aragón	Spain	50009
3	Hospital Virgen Salud	Toledo	Castilla La Mancha	Spain	45071
4	Hospital Universitario Burgos	Burgos	Castilla y León	Spain	09006
5	Hospital Clínico Salamanca	Salamanca	Castilla y León	Spain	37007
6	Hospital Clínico Valladolid	Valladolid	Castilla y León	Spain	47005:
7	Hospital Vall d´Hebron	Barcelona	Cataluña	Spain	08035
8	Hospital Universitario San Joan Reus	Reus	Cataluña	Spain	43204
9	Hospital Infanta Cristina	Badajoz	Extremadura	Spain	06006
10	Capio Clideba	Badajoz	Extremadura	Spain	06011
11	Complejo Hospitalario Orense	Orense	Galicia	Spain	32005
12	Hospital Santa Lucía	Cartagena	Murcia	Spain	30202
13	Hospital Navarra	Pamplona	Navarra	Spain	31008
14	Hospital Gregorio Marañón	Madrid		Spain	28007:
15	MD Anderson	Madrid		Spain	28033
16	Hospital Clínico San Carlos	Madrid		Spain	28040
17	Hospital 12 octubre	Madrid		Spain	28041
18	Hospital Quirón	Madrid		Spain	28223
19	Hospital Morales Meseguer	Murcia		Spain	30008